Evidence map›Paper›PMID 36256662›Full record

ArticlePloS one2022

Health care use and spending for Medicaid patients diagnosed with opioid use disorder receiving primary care in Federally Qualified Health Centers and other primary care settings.

Lauren Peterson, Manoradhan Murugesan, Robert Nocon, Hank Hoang, Joshua Bolton, Neda Laiteerapong, Harold Pollack, Jeanne Marsh

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Lauren PetersonCrown Family School of Social Work, Policy, and Practice, University of Chicago, Chicago, Illinois, United States of America.ORCID 0000-0002-6625-4973
Manoradhan MurugesanDepartment of Public Health Sciences, University of Chicago, Chicago, IL, United States of America.
Robert NoconDepartment of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, United States of America.
Hank HoangHealth Resources and Services Administration, U.S. Department of Health and Human Services, Rockville, Maryland, United States of America.
Joshua BoltonHealth Resources and Services Administration, U.S. Department of Health and Human Services, Rockville, Maryland, United States of America.
Neda LaiteerapongDepartment of Medicine, University of Chicago, Chicago, Illinois, United States of America.
Harold PollackCrown Family School of Social Work, Policy, and Practice, University of Chicago, Chicago, Illinois, United States of America.
Jeanne MarshCrown Family School of Social Work, Policy, and Practice, University of Chicago, Chicago, Illinois, United States of America.ORCID 0000-0001-6289-4474
University of Chicago · USChicago Department of Public Health · USHealth Resources and Services Administration · USKaiser Permanente · US

Funding

Research Design, Data, and Analytics CoreP30DK092949 · NIDDK · UNIVERSITY OF CHICAGO · PI ELBERT S. HUANG · 2011 to 2026
$10.0M
Gender Disparities in Access and Engagement in Medication-Assisted Treatment for Opioid Use DisorderR01DA048176 · NIDA · UNIVERSITY OF CHICAGO · PI GUERRERO, ERICK, MARSH, JEANNE C · 2019 to 2022
$2.0M
AHRQ HHS T32 HS000084NIDA NIH HHS R01 DA048176NIDDK NIH HHS P30 DK092949
6 · The paper itself

Abstract

introductionThis nationwide study builds on prior research, which suggests that Federally Qualified Health Centers (FQHCs) and other primary care providers are associated with increased access to opioid use disorder (OUD) treatment. We compare health care utilization, spending, and quality for Medicaid patients diagnosed with OUD who receive primary care at FQHCs and Medicaid patients who receive most primary care in other settings, such as physician offices (non-FQHCs). We hypothesized that the integrated care model of FQHCs would be associated with greater access to medication for opioid use disorder (MOUD) and/or behavioral health therapy and lower rates of potentially inappropriate co-prescribing.

methodsThis cross-sectional study examined 2012 Medicaid Analytic eXtract files for patients diagnosed with OUD receiving most (>50%) primary care at FQHCs (N = 37,142) versus non-FQHCs (N = 196,712) in all 50 states and Washington DC. We used propensity score overlap weighting to adjust for measurable confounding between patients who received care at FQHCs versus non-FQHCs and increase generalizability of findings given variation in Medicaid programs and substance use policies across states.

resultsFQHC patients displayed higher primary care utilization and fee-for-service spending, and similar or lower utilization and fee-for-service spending for other health service categories. Contrary to our hypotheses, non-FQHC patients were more likely to receive timely (≤90 days) MOUD (buprenorphine, methadone, naltrexone, or suboxone) (Relative Risk [RR] = 1.10, 95% CI: 1.07, 1.12) and more likely be retained in medication treatment (>180 days) (RR = 1.12, 95% CI: 1.09, 1.14). However, non-FQHC patients were less likely to receive behavioral health therapy (mental health or substance use therapy) (RR = 0.90, 95% CI: 0.88, 0.92) and less likely to remain in behavioral health treatment (RR = 0.92, 95% CI: 0.89, 0.94). Non-FQHC patients were more likely to fill potentially inappropriate prescriptions of benzodiazepines and opioids after OUD diagnosis (RR = 1.35, 95% CI: 1.30, 1.40).

conclusionsObserved patterns suggest that Medicaid patients diagnosed with OUD who obtained primary care at FQHCs received more integrated care compared to non-FQHC patients. Greater care integration may be associated with increased access to behavioral health therapy and quality of care (lower potentially inappropriate co-prescribing) but not necessarily greater access to MOUD.

Indexed as

BuprenorphineOpioid-Related DisordersAnalgesics, OpioidBenzodiazepinesBuprenorphine, Naloxone Drug CombinationCross-Sectional StudiesDelivery of Health CareHumansMedicaidMethadoneNaltrexonePrimary Health CareUnited StatesAnalgesics, OpioidBenzodiazepinesBuprenorphineBuprenorphine, Naloxone Drug CombinationMethadoneNaltrexone

Identifiers

PMID36256662
PMCPMC9578596
OpenAlexW4306711218

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.